AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 179 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $810,272,000 | +110.8% | 53,554 | +4.5% | 0.00% | – |
| Q2 2022 | $384,332,000 | -22.9% | 51,244 | -6.5% | 0.00% | – |
| Q1 2022 | $498,617,000 | +29.6% | 54,793 | 0.0% | 0.00% | – |
| Q4 2021 | $384,648,000 | -38.4% | 54,793 | 0.0% | 0.00% | – |
| Q3 2021 | $624,640,000 | -28.7% | 54,793 | +0.1% | 0.00% | – |
| Q2 2021 | $876,164,000 | +16.5% | 54,726 | +30.1% | 0.00% | – |
| Q1 2021 | $751,898,000 | +32.3% | 42,076 | 0.0% | 0.00% | – |
| Q4 2020 | $568,446,000 | +14.8% | 42,076 | 0.0% | 0.00% | – |
| Q3 2020 | $495,234,000 | -22.4% | 42,076 | -2.7% | 0.00% | – |
| Q2 2020 | $638,283,000 | +13.3% | 43,244 | +3.6% | 0.00% | – |
| Q1 2020 | $563,249,000 | -38.9% | 41,722 | +9.4% | 0.00% | -100.0% |
| Q4 2019 | $921,747,000 | +56.9% | 38,136 | +24.8% | 0.00% | – |
| Q3 2019 | $587,382,000 | -26.0% | 30,561 | +13.8% | 0.00% | -100.0% |
| Q2 2019 | $793,772,000 | -46.3% | 26,862 | -13.7% | 0.00% | 0.0% |
| Q1 2019 | $1,479,342,000 | -60.4% | 31,144 | -69.9% | 0.00% | -66.7% |
| Q4 2018 | $3,738,083,000 | -42.2% | 103,548 | -1.5% | 0.00% | -40.0% |
| Q3 2018 | $6,472,598,000 | -3.8% | 105,160 | +5.6% | 0.01% | 0.0% |
| Q2 2018 | $6,729,601,000 | +13.3% | 99,624 | -9.0% | 0.01% | 0.0% |
| Q1 2018 | $5,937,230,000 | -13.5% | 109,442 | -4.7% | 0.01% | -16.7% |
| Q4 2017 | $6,860,077,000 | +247.0% | 114,813 | +182.2% | 0.01% | +200.0% |
| Q3 2017 | $1,977,193,000 | +119.2% | 40,683 | +137.1% | 0.00% | +100.0% |
| Q2 2017 | $901,811,000 | +60.0% | 17,161 | +38.1% | 0.00% | 0.0% |
| Q1 2017 | $563,701,000 | +236749.2% | 12,430 | +97.3% | 0.00% | – |
| Q4 2016 | $238,000 | -46.2% | 6,300 | -46.2% | 0.00% | – |
| Q3 2016 | $442,000 | +97.3% | 11,700 | +27.2% | 0.00% | – |
| Q4 2015 | $224,000 | +7.7% | 9,200 | -21.4% | 0.00% | – |
| Q3 2015 | $208,000 | -11.5% | 11,700 | -12.0% | 0.00% | – |
| Q2 2015 | $235,000 | -7.5% | 13,300 | +64.2% | 0.00% | – |
| Q1 2015 | $254,000 | – | 8,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |